Combining Mathematical Modelling with In-Vitro Experiments to Predict In-Vivo Drug-Eluting Stent Kinetics

In this paper we describe a combined in-vitro experimental and mathematical modelling approach to predict in-vivo drug-eluting stent kinetics. We coated stents with a mixture of sirolimus and a novel acrylic-based polymer in two different ratios. Our results indicate differential release kinetics between low and high drug dose formulations. Furthermore, mathematical model simulations of target receptor saturation suggest potential differences in efficacy

Short and long-term acceptability and efficacy of extended-release cornstarch in the hepatic glycogen storage diseases: results from the Glyde study

Background: Hypoglycaemia is the primary manifestation of all the hepatic types of glycogen storage disease (GSD). In 2008, Glycosade®, an extended-release waxy maize cornstarch, was reported as an alternative to uncooked cornstarch (UCCS) which could prolong the duration of fasting in the GSD population. To date, there has been minimal published experience in (a) young children, (b) the ketotic forms of GSD, and (c) with daytime dosing. The Glyde study was created as a prospective, global initiative to test the efficacy and tolerance of Glycosade use across a broader and more diverse population. Methods: A randomised double-blind cross-over fasting study assessing the tolerance and efficacy of Glycosade compared with cornstarch was performed across disease types and ages. Participants and clinicians chose the product deemed superior, whilst still blinded. Participants were followed for 2 years to assess long-term metabolic control, growth, and quality of life. Results: Sixty-one participants (age 2–62 years; 59% female) were enrolled, and 58 participants completed the fasting studies (28 GSD I; 30 GSD III, VI, IX). Glycosade improved duration of fasting in GSD I and duration of fasting without ketosis in the ketotic forms. Chronic Glycosade use was chosen by 69% of participants. Those treated with Glycosade for the 2-year chronic phase used fewer doses of therapy while markers of metabolic control remained stable. Conclusion: The Glyde study is the first multi-centre international trial demonstrating the efficacy and tolerance of Glycosade in a large cohort of hepatic GSD patients across a diverse international population. The ability to use fewer doses of therapy per day and avoidance of overnight therapy may improve compliance, safety, and quality of life without sacrificing metabolic control

FERRY: access control and quota management service

Fermilab developed the Frontier Experiments RegistRY (FERRY) service that provides a centralized repository for access control and job management attributes such as batch and storage access policies, quotas, batch priorities and NIS attributes for cluster configuration. This paper describes the FERRY architecture, deployment and integration with services that consume the stored information. The Grid community has developed several access control management services over the last decade. Over time, services for Fermilab experiments have required the collection and management of more access control and quota attributes. At the same time, various services used for this purpose, namely VOMS-Admin, GUMS and VULCAN, are being abandoned by the community. FERRY has multiple goals: maintaining a central repository for currently scattered information related to users' attributes, providing a Restful API that allows uniform data retrieval by services, and providing a replacement service for all the abandoned grid services. FERRY is integrated with the ServiceNow (SNOW) ticketing service and uses it as its user interface. In addition to the standard workflows for request approval and task creation, SNOW invokes orchestration that automates access to FERRY API. Our expectation is that FERRY will drastically improve user experience as well as decrease effort required by service administrators

FERRY: access control and quota management service

Fermilab developed the Frontier Experiments RegistRY (FERRY) service that provides a centralized repository for access control and job management attributes such as batch and storage access policies, quotas, batch priorities and NIS attributes for cluster configuration. This paper describes the FERRY architecture, deployment and integration with services that consume the stored information. The Grid community has developed several access control management services over the last decade. Over time, services for Fermilab experiments have required the collection and management of more access control and quota attributes. At the same time, various services used for this purpose, namely VOMS-Admin, GUMS and VULCAN, are being abandoned by the community. FERRY has multiple goals: maintaining a central repository for currently scattered information related to users' attributes, providing a Restful API that allows uniform data retrieval by services, and providing a replacement service for all the abandoned grid services. FERRY is integrated with the ServiceNow (SNOW) ticketing service and uses it as its user interface. In addition to the standard workflows for request approval and task creation, SNOW invokes orchestration that automates access to FERRY API. Our expectation is that FERRY will drastically improve user experience as well as decrease effort required by service administrators